Thus, while preliminary data on PCSK9 inhibitors are promising, rigorous clinical trials are essential to determine their role in the management of portal hypertension and their potential as adjunctive therapies in the treatment of liver diseases. The gene discussed is PCSK9; the disease is portal hypertension.